Please assess the completion status of the following clinical trial:

Trial Title: Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with pulmonary emphysema due to severe congenital AAT deficiency of phenotype protease inhibitor Z (PiZ) or other rare genotypes (not MS, MZ or SZ) and AAT serum level \< 11 microns (µM) or \< 80 mg/dL (status to be confirmed by phenotyping and genotyping)~* Inspiratory capacity (VC - ERV) \> 1.2 L and forced expiratory volume at one second (FEV1) \< 80% of predicted value post bronchodilator~* FEV1/VC \< 70% of predicted value post-bronchodilator or transfer factor of carbon monoxide (KCO) \< 80% of predicted value post-bronchodilator~* History of at least one exacerbation in the past 2 years~* Written informed consent~Exclusion Criteria:~* FEV1 \< 25% of predicted value post-bronchodilator~* Augmentation therapy for more than one month with plasma-derived human alpha 1-antitrypsin (AAT) within the last 2 years~* History of lung transplant~* Any lung surgery within the past 2 years~* On any thoracic surgery waiting list~* Diagnosis of liver cirrhosis~* Severe concomitant disease~* Active pulmonary infection/exacerbations within the last month~* Active smoking during the last 6 months or plasma positive for cotinine~* Body weight \< 42 kg or \> 92 kg~* Pregnancy or lactation~* Women of child-bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Prolastin
- Group 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).